Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8351747 | Pharmacology Biochemistry and Behavior | 2013 | 6 Pages |
Abstract
Accumulating evidence suggests that soluble epoxide hydrolase (sEH) plays a key role in controlling levels of lipid signaling molecules, and that the potent sEH inhibitors may be potential therapeutic drugs for a number of diseases associated with metabolism of epoxyeicosatrienoic acids (EETs). This study was undertaken to examine whether the potent sEH inhibitor AS2586114 could attenuate behavioral abnormalities (e.g., hyperlocomotion and prepulse inhibition (PPI) deficits) in male ddY mice after a single administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP). A single oral administration of AS2586114 (10, 30, or 100Â mg/kg) attenuated the hyperlocomotion in mice after the administration of PCP (3.0Â mg/kg, s.c.), in a dose dependent manner. Furthermore, a single oral administration of AS2586114 (10, 30, or 100Â mg/kg) improved the PPI deficits in mice after the administration of PCP (3.0Â mg/kg, s.c.), in a dose dependent manner. In addition, the atypical antipsychotic drug clozapine (10Â mg/kg, p.o.) significantly attenuated hyperlocomotion and PPI deficits after the administration of PCP (3.0Â mg/kg, s.c.). In conclusion, this study suggests that AS2586114 may have antipsychotic activity in PCP models of schizophrenia. Therefore, it is likely that the sEH inhibitors may be potential therapeutic drugs for neuropsychiatric diseases such as schizophrenia.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Min Ma, Qian Ren, Yuko Fujita, Tamaki Ishima, Ji-Chun Zhang, Kenji Hashimoto,